Primary Angioplasty Compared with Thrombolysis: New Issues in the Era of Glycoprotein IIb/IIIa Inhibition and Intracoronary Stenting
- 18 May 1999
- journal article
- research article
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 130 (10) , 841-847
- https://doi.org/10.7326/0003-4819-130-10-199905180-00019
Abstract
The past decade has witnessed a dramatic expansion in the scope of both mechanical and pharmacologic methods for opening occluded arteries in patients with acute myocardial infarction. Although the relative merits of conventional balloon angioplasty and thrombolysis have been evaluated, this old debate is being eclipsed by new comparisons. New device technologies, such as intracoronary stenting; more potent and more fibrin-specific thrombolytic agents; and new antithrombotic and antiplatelet agents all offer the potential for improved outcomes. But despite these recent developments, the time-dependent open artery hypothesis--which states that the achievement of early, full, and sustained reperfusion is associated with better outcomes--remains essentially unchanged. This article reviews data on the ability of six revascularization strategies--stand-alone thrombolysis, conventional percutaneous transluminal coronary angioplasty, stenting, glycoprotein IIb/IIIa inhibitors plus thrombolytic agents, glycoprotein IIb/IIIa inhibitors plus interventions, and the combination of pharmacologic and mechanical interventions--to produce early, full, and sustained reperfusion.Keywords
This publication has 28 references indexed in Scilit:
- Survival benefit of Abciximab administration during early rescue angioplasty: analysis of 387 patients from the GUSTO-III trialJournal of the American College of Cardiology, 1998
- Abciximab (ReoPro) potentiates thrombolysis in ST elevation myocardial infarction: results of TIMI 14 trialsJournal of the American College of Cardiology, 1998
- Comparison of Primary Coronary Angioplasty and Intravenous Thrombolytic Therapy for Acute Myocardial InfarctionJAMA, 1997
- A Prospective, Randomized, Double-Blind Multicenter Trial of a Single Bolus Injection of the Novel Modified t-PA E6010 in the Treatment of Acute Myocardial Infarction: Comparison With Native t-PAJournal of the American College of Cardiology, 1997
- Influence of door-to-balloon time on mortality in primary angioplasty results in 3,648 patients in the second national registry of myocardial infarction (NRMI-2)Journal of the American College of Cardiology, 1996
- Immediate coronary angioplasty versus intravenous streptokinase in acute myocardial infarction: Left ventricular ejection fraction, hospital mortality and reinfarctionJournal of the American College of Cardiology, 1994
- Profound inhibition of platelet aggregation with monoclonal antibody 7E3 Fab thrombolytic therapy: Results of the thrombolysis and angioplasty in mycardial infaraction (TAMI) 8 pilot studyJournal of the American College of Cardiology, 1993
- Randomized trial of direct coronary angioplasty versus intravenous streptokinase in acute myocardial infarctionJournal of the American College of Cardiology, 1993
- Immediate vs Delayed Catheterization and Angioplasty Following Thrombolytic Therapy for Acute Myocardial InfarctionJAMA, 1988
- THROMBOLYSIS WITH TISSUE PLASMINOGEN ACTIVATOR IN ACUTE MYOCARDIAL INFARCTION: NO ADDITIONAL BENEFIT FROM IMMEDIATE PERCUTANEOUS CORONARY ANGIOPLASTYThe Lancet, 1988